Scienza e Tecnologia
Telix Urology Innovation Showcase to be held at The Yale Club, New York City
Briefing session agenda:
Shareholders wishing to attend this briefing session in person are required to register their attendance through this link.
The briefing session will also be broadcast live via webcast for shareholders who cannot attend in person. Please register at this link for the live webcast.
A recording of the event will also be made available on the Company's website.
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on Twitter (@TelixPharma) and LinkedIn.
TLX250-CDx and TLX591 have not received a marketing authorisation in any jurisdiction. Telix's lead product, gallium-68 ( Ga) gozetotide (also known as Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA), and by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. Telix is also progressing a marketing authorisation application for this investigational candidate in the United Kingdom and the European Union.
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com
Lisa Wilson
In-Site Communications
Email: lwilson@insitecony.com
Legal Notices
[3] Telix ASX disclosure 20 December 2021.
[4] Telix ASX disclosure 2 November 2021.
[5] Telix ASX disclosure 14 October 2022.
[6] Telix ASX disclosure 3 April 2023.
Logo - https://mma.prnewswire.com/media/1920208/TeliMain_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/telix-urology-innovation-showcase-to-be-held-at-the-yale-club-new-york-city-301856001.html